ReviewInternational journal of hematology2011
Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
Review in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 75 citations in OpenAlex.
- Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.Scientific reports · 2021Trial
- Genetic, epigenetic, and molecular determinants of multiple myeloma and precursor plasma cell disorders: a pathophysiological overview.Medical oncology (Northwood, London, England) · 2025Review
- Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature.Current oncology (Toronto, Ont.) · 2025Review
- Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression.Molecular medicine reports · 2022Article
- Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.Journal of biomedical science · 2022Article
- Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.Frontiers in oncology · 2022Review
- Review
- Reelin depletion alleviates multiple myeloma bone disease by promoting osteogenesis and inhibiting osteolysis.Cell death discovery · 2021Article
- Revealing dynamic regulations and the related key proteins of myeloma-initiating cells by integrating experimental data into a systems biological model.Bioinformatics (Oxford, England) · 2021Article
- Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?Journal of bone oncology · 2021Article
- Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling.Cancers · 2020Review
- Article
- IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression.Translational oncology · 2019Article
- Modelling cancer in microfluidic human organs-on-chips.Nature reviews. Cancer · 2019Review
- Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma.Frontiers in oncology · 2019Review
- TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.Blood advances · 2017Article
- Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Journal of leukocyte biology · 2017Review
- The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.Oncology letters · 2017Article
- Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.Theranostics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular interplay in the bone marrow (BM) microenvironment in multiple myeloma (MM) mediates MM growth and the formation of bone-destructive lesions. MM cells show enhanced osteoclastogenesis, and stimulate angiogenesis in concert with BM stromal cells and osteoclasts, whereas they suppress osteoblastic differentiation, leading to devastating bone destruction and the rapid loss of bone. Importantly, osteoclasts, vascular endothelial cells, and BM stromal cells with defective osteoblastic differentiation create a cellular microenvironment suitable for MM growth and survival and confer a drug resistance to MM cells, which can be construed as the "MM niche". Therefore, the MM niche must be targeted and disrupted to improve the efficacy of anti-tumor treatment and prevent the progression of bone disease in MM. Clarifying molecular mechanisms leading to the formation of the MM niche along with bone disease will help in the development of novel approaches targeting the interplay between MM cells and the BM microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.